T A B L E O F C O N T E N
A subgroup analysis of major outcomes by type of oximeter calibration software (original versus revised) found a significant difference in the treatment effect between the two software types for death (interaction P = 0.03), with a significantly larger treatment effect seen for those infants using the revised algorithm (typical RR 1.38, 95% CI 1.13 to 1.68; typical RD 0.06, 95% CI 0.01 to 0.10; 3 trials, 1716 infants). There were no other important differences in treatment effect shown by the subgroup analyses using the currently available data.
Authors' conclusions
In extremely preterm infants, targeting lower (85% to 89%) SpO compared to higher (91% to 95%) SpO had no significant effect on the composite outcome of death or major disability or on major disability alone, including blindness, but increased the average risk of mortality by 28 per 1000 infants treated. The trade-offs between the benefits and harms of the different oxygen saturation target ranges may need to be assessed within local settings (e.g. alarm limit settings, staffing, baseline outcome risks) when deciding on oxygen saturation targeting policies.
P L A I N L A N G U A G E S U M M A R Y

Targeting lower or higher oxygen levels in preterm infants
Review question: Is it better to target a lower or higher level of oxygen for babies born very early?
Background: Giving additional ('supplemental') oxygen to babies born very early ('extremely preterm infants') who have breathing difficulties has been common practice since the 1940s. Despite this, there is little agreement as to what levels of oxygen will maximise short-or long-term survival and development. Technology ('pulse oximetry') that can easily measure the level of oxygen in a baby's blood (oxygen saturation) has been in widespread use since the 1990s. Despite this, until recently there were no randomised trials
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B A C K G R O U N D Description of the condition
The administration of supplemental oxygen has a long history in neonatal care (Wilson 1942; Tin 2007) . Oxygen was used liberally for the first time in neonates in the 1930s when an oxygen unit was described for preterm infants (Raju 1999) . The use of oxygen in preterm and low birth weight infants suffering respiratory insufficiency has resulted in significant healthcare benefits, such as reduced mortality and spastic diplegia (Avery 1960; McDonald 1963) , but has also been associated with significant deleterious effects such as retinopathy of prematurity and lung toxicity (Duc 1992) . Improvements in technology in the past few decades have led to the increased survival of preterm and low birth weight infants.
One of these advances is the ability to measure oxygen levels more accurately. Despite the exceedingly common use of supplemental oxygen in this population of infants, there is little consensus as to the optimal levels of oxygen for maximising short-or long-term growth and development, while minimising harmful effects (Poets 1998; McIntosh 2001; Silverman 2004) .
Adverse consequences of liberal and restricted use of oxygen
The adverse consequences of liberal oxygen use were recognised in the early 1940s. Terry 1942 described a type of blindness in preterm infants characterised by a thick fibrotic membrane in the retrolental space. In 1951, the role of supplemental oxygen in the aetiology of 'retrolental fibroplasia' was first suggested (Campbell 1951) . By 1954, retrolental fibroplasia had blinded about 10,000 infants (Silverman 1980; Silverman 2004) . From 1954 to 1956 , three randomised trials (Lanman 1954 Patz 1954; Kinsey 1956) , enrolling 341 infants, proved that breathing unrestricted concentrations of inspired oxygen was a major cause of retrolental fibroplasia (Askie 2009). Throughout this period, oxygen administration was guided by the clinical observations of skin colour, as well as the rate, regularity and work of breathing. It was not until the 1960s and 1970s that sampling of blood gases, transcutaneous oxygen monitoring and later pulse oximetry became available for more precise monitoring of oxygen levels (Walsh 2009 ). An early prospective cohort study, reported in 1977, was unable to establish a causal relationship between arterial oxygen tension and (what is now known as) retinopathy of prematurity (ROP), but did reveal that the most relevant factors for developing ROP were birth weight less than 1200 grams and length of exposure to supplemental oxygen (Kinsey 1977) . As a consequence of the retrolental fibroplasia blindness epidemic in the 1960s, the use of oxygen was drastically limited, usually to less than 40% inspired oxygen, even for preterm infants with respiratory distress, allowing them to become severely hypoxaemic and leading to a substantial increase in the incidence of cerebral palsy (Usher 1961). In the next 20 years over 150,000 premature babies died of hypoxic respiratory failure (Avery 1960; McDonald 1964; Cross 1973; Bolton 1974) . It is estimated that for every infant whose sight was saved, 16 died (Avery 1960; Silverman 2004) , and many others developed spastic diplegia (McDonald 1964) .
Description of the intervention
Multiple attempts have been made to establish the optimal oxygen levels in preterm infants, using a variety of technologies, in order to circumvent the adverse consequences of either restricted or liberal use of supplemental oxygen. However, what constitutes an 'appropriate' level of oxygen for infants born preterm, who would otherwise be in-utero, remains unknown. The fetus is relatively hypoxic with haemoglobin (Hb) oxygen saturations of 65%, 55%, and 45% in the aorta, pulmonary artery and pulmonary vein, respectively. However, it should be noted that fetal blood contains almost only fetal haemoglobin (HbF), which has an extraordinary affinity for oxygen and is therefore capable of capturing sufficient oxygen from the intervillous space to support fetal growth and metabolism (Gao 2010; Vento 2013) .
In the 1980s and early 1990s the use of transcutaneous oxygen monitoring became available. A study of transcutaneous oxygen monitoring (TcO ) in preterm infants confirmed that ROP occurred more often when longer periods of time were spent with a TcO above 80 mm Hg, but did not determine if another limit was safer (Flynn 1992) . A partial pressure of arterial oxygen (PaO ) range of 50 to 80 mm Hg became widely accepted as an appropriate level to target (AAP 1988; McIntosh 2001; AAP 2002) , but this was based on professional consensus rather than on evidence.
In the 1990s the use of pulse oximetry became a standard of care and continuous monitoring has allowed more frequent titration of the oxygen concentration administered. Pulse oximetry (SpO ) refers to the estimation of the oxygen saturation of arterial blood using a device that measures the pulsatile changes in light transmission across a tissue bed. Pulse oximeters work on the principle that oxygenated and deoxygenated haemoglobin absorbs light of different wavelengths (red and infrared). The oximeter emits light of these two wavelengths and measures absorption in the pulsatile element of the blood flow, thus producing a measure of the oxygen saturation of arterial blood separate from the non-pulsatile venous blood (Williams 1998 
How the intervention might work
Oxygen is the most common therapy used in the care of very preterm infants. It has been associated with significant improvements in neonatal survival and reduced disability (Avery 1960 
Why it is important to do this review
Extreme prematurity of less than 28 weeks' gestation affects approximately 1% of births (Centre for Epi 2012). Although approximately 80% of these infants are discharged home alive (Chow 2013), they often sustain severe morbidity (Doyle 2010), including chronic lung disease, poor growth, respiratory illness, hospital re-admissions, visual deficits, cerebral palsy, neurodevelopmental disability and cognitive, educational, and behavioural impairment (Anderson 2003) . It is essential to determine whether the range of targeted SpO levels affects the occurrence of such outcomes and, if possible, to determine the optimal range for management of the very vulnerable preterm infant. Very preterm infants account for a high proportion of the costs and disability from neonatal intensive care (Sutton 1999) . Reducing these morbidities would enhance quality of life for these infants and benefit their families and communities (Saigal 2000) .
O B J E C T I V E S
1. What are the effects of targeting lower versus higher oxygen saturation ranges on death or major neonatal and infant morbidities, or both, in extremely preterm infants? 2. Do these effects differ in different types of infants, including those born at a very early gestational age, or in those who are outborn, without antenatal corticosteroid coverage, of male sex, small for gestational age or of multiple birth, or by mode of delivery?
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials. We excluded quasirandomised trials and cluster-randomised trials.
Types of participants
Participants in the eligible trials were infants either inborn or outborn before 28 weeks' gestation.
Types of interventions
The intervention was the used of pulse oximetry to target either a lower (SpO less than or equal to 90%) or higher (SpO greater than 90%) oxygen saturation range by 24 hours after birth, maintaining these ranges for at least the first two weeks of life. There was no minimum required level of compliance for keeping within the target ranges. Oxygen targeting could be achieved by either manual or machine-assisted methods.
Types of outcome measures
We assessed longer-term outcomes in infancy from 18 months corrected for gestational age onwards, depending on the measurement time point used by individual trials.
Primary outcomes
• Composite outcome of death or major disability by 18 to 24 months corrected for gestational age (aligned definition, trialist defined)
Secondary outcomes
• Death (to discharge, to 18 to 24 months corrected for gestational age follow-up)
• Major disability by 18 to 24 months corrected for gestational age (aligned definition, trialist defined)
• Retinopathy of prematurity (ROP) treatment by laser photocoagulation, cryotherapy or bevacizumab treatment
• Measures of respiratory support, defined as (a) supplemental oxygen requirement at 36 weeks postmenstrual age (trialist defined), (b) days of endotracheal intubation, (c) days of continuous positive airway pressure (CPAP), (d) days of supplemental oxygen, (e) days on home oxygen
• Patent ductus arteriosus requiring medical treatment (defined as using cyclo-oxygenase inhibitors) or surgical treatment
• Necrotising enterocolitis • Weight at 36 weeks postmenstrual age, discharge home and 18 or 24 months corrected for gestational age
• Proportion of infants re-admitted to hospital up to 18 to 24 months corrected for gestational age 
Searching other resources
We searched previous reviews and cross-references, abstracts, and conference and symposia proceedings. We contacted expert informants and carried out journal handsearching. We searched the abstracts of the relevant perinatal meetings (including Society for Pediatric Research, Neonatal Register) for the years 1985 to the present, using the following keywords: 'oxygen saturation'. For abstract books that did not include keywords, we limited the search to the relevant sections, such as pulmonology and neonatology.
Data collection and analysis
We used the methods of Cochrane Neonatal for data collection and analysis.
Selection of studies
LA, BD, and PD independently reviewed the results of the search and selected studies for inclusion.
Data extraction and management
We used a data extraction form specifically designed for this review. We collected information on the following outcome variables:
• composite outcome of death or major disability by 18 to 24 months corrected for gestational age;
• death (to discharge, to 18 to 24 months follow-up);
• major disability by 18 to 24 months corrected for gestational age;
• ROP treatment by laser photocoagulation, cryotherapy or bevacizumab treatment (performed if threshold ROP occurs);
• measures of respiratory support, defined as (a) supplemental oxygen requirement at 36 weeks postmenstrual age, (b) days of endotracheal intubation, (c) days of CPAP, (d) days of supplemental oxygen, (e) days on home oxygen; patent ductus arteriosus requiring medical treatment (defined as using cyclooxygenase inhibitors) or surgical treatment;
• necrotising enterocolitis (trialist defined);
• weight at 36 weeks postmenstrual age, discharge home and 18 and 24 months corrected for gestational age;
• re-admissions to hospital up to 18 to 24 months corrected for gestational age;
• cerebral palsy with GMFCS level 2 or higher or MACS level 2 or higher at 18 to 24 months corrected for gestational age;
• blindness (< 6/60 vision, 1.3 logMAR in both eyes);
• severe hearing loss;
• quantitative Bayley III scores.
We resolved differences in assessment by discussion or by involving the remaining review authors. For each study, one review author (LA) extracted, assessed, and coded all data for each included study and entered final data into Review Manager 5 (RevMan 2014). A second review author (RW) checked these data for accuracy and each of the authors from the included trials also checked the accuracy of their own trial data. We resolved discrepancies through discussion. We contacted the authors of the original reports to provide further details when information regarding any of the above was unclear.
Assessment of risk of bias in included studies
We used the standard methods of Cochrane Neonatal. LA and RW independently assessed the risk of bias for each study using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). RW prepared the initial 'Risk of bias' tables for discussion. Disagreements were resolved by discussion or by involving the remaining review authors and members of the NeOProM Collaboration.
We assessed the methodological quality of the studies using the following criteria:
• Sequence generation (checking for possible selection bias). For each included study, we categorised the method used to generate the allocation sequence as:
• low risk (any truly random process, e.g. random number table; computer random number generator);
• high risk (any non-random process, e.g. odd or even date of birth; hospital or clinic record number);
• unclear risk.
• Allocation concealment (checking for possible selection bias). For each included study, we categorised the method used to conceal the allocation sequence as:
• low risk (e.g. telephone or central randomisation; consecutively numbered, sealed, opaque envelopes);
• high risk (open random allocation; unsealed or nonopaque envelopes; alternation; date of birth);
• unclear risk. • Blinding (checking for possible performance bias). For each included study, we categorised the methods used to blind study participants and personnel from knowledge of which intervention a participant received. We assessed blinding separately for different outcomes or classes of outcomes. We categorised the methods as:
• low risk, high risk or unclear risk for participants;
• low risk, high risk or unclear risk for personnel;
• low risk, high risk or unclear risk for outcome assessors.
• Incomplete outcome data (checking for possible attrition bias through withdrawals, dropouts, protocol deviations). For each included study and for each outcome, we described the completeness of data including attrition and exclusions from the analysis. We noted whether attrition and exclusions were reported, the numbers included in the analysis at each stage (compared with the total randomised participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups or were related to outcomes. We categorised the methods as:
• low risk (less than 20% missing data);
• high risk (20% or more missing data);
• Selective reporting bias. For each included study, we described how we investigated the possibility of selective outcome reporting bias and what we found. We assessed the methods as:
• low risk (where it is clear that all of the study's prespecified outcomes and all expected outcomes of interest to the review have been reported);
• high risk (where not all the study's prespecified outcomes have been reported; one or more reported primary outcomes were not prespecified; outcomes of interest are reported incompletely and so cannot be used; study fails to include results of a key outcome that would have been expected to have been reported);
• Other sources of bias. For each included study, we described any important concerns we had about other possible sources of bias (for example, whether there was a potential source of bias related to the specific study design or whether the trial was stopped early due to some data-dependent process or interim analyses issues, or both). We assessed whether each study was free of other problems that could put it at risk of bias as follows:
• low risk;
• high risk;
• Overall risk of bias (described in Table 8 .5c in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011)).
We made explicit judgements regarding whether studies were at high risk of bias, according to the criteria given in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). With reference to (1) to (6) above, we assessed the likely magnitude and direction of the bias and whether we considered it is likely to have an impact on the findings. If need be, we planned to explore the impact of the level of bias through undertaking sensitivity analyses (see Sensitivity analysis below).
Measures of treatment effect
We used the standard methods of Cochrane Neonatal to analyse data. We performed statistical analyses using Review Manager 5 software (RevMan 2014). We analysed dichotomous data using the risk ratio (RR), risk difference (RD), and the number needed to treat for an additional beneficial outcome (NNTB) or number needed to treat for an additional harmful outcome (NNTH). We included the 95% confidence interval (CI) for all estimates. For the purposes of the analysis, we considered the lower target range group to be the treatment or experimental group and the higher target range group to be the control group. We analysed continuous data using the mean difference (MD) or the standardised mean difference (SMD) to combine trials that measured the same outcome but used different methods.
Unit of analysis issues
The unit of analysis was each infant randomised.
Dealing with missing data
For the included studies we noted levels of attrition. We explored the impact of including studies with high levels of missing data in the overall assessment of treatment effect using sensitivity analyses. We analysed all outcomes on an intention-to-treat basis, i.e. we included all participants randomised to each group in the analyses. We did not replace missing data by imputation: the denominator for each outcome in each trial was the number randomised minus any participants whose outcomes were known to be missing.
Assessment of heterogeneity
We examined heterogeneity between trials by first assessing differences in trial methodologies and clinical heterogeneity. If we judged clinical heterogeneity to be absent, we then quantified the impact of heterogeneity using the I² statistic (less than 25%, no heterogeneity; 25% to 49%, low heterogeneity; 50% to 74%, moderate heterogeneity; and 75% or more, high heterogeneity) (Higgins 2003; Higgins 2011) . If heterogeneity was detected, we explored the possible causes of statistical heterogeneity using prespecified subgroup analysis (for example, differences in study quality, participant or intervention characteristics).
Assessment of reporting biases
We assessed possible publication bias and other biases using symmetry/asymmetry of funnel plots, if there were sufficient trials to allow these analyses. For included trials that were recently performed (and therefore prospectively registered), we explored possible selective reporting of study outcomes by comparing the primary and secondary outcomes in the reports with the primary and secondary outcomes proposed at trial registration, using the website www.who.int/ ictrp. If we found such discrepancies, we contacted the primary investigators to interpret variances with outcomes prespecified at trial registration.
Data synthesis
We conducted the meta-analysis using Review Manager 5 software (RevMan 2014), supplied by Cochrane. We used the MantelHaenszel method for estimates of typical risk ratio and risk difference. We analysed any continuous measures using the inverse variance method. We used the fixed-effect model for all meta-analyses.
Quality of evidence
We used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, as outlined in the GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations (Schünemann 2013) , to assess the quality of evidence for the following major outcomes: death or major disability by 18 to 24 months corrected age (aligned definition); death to 18 to 24 months corrected age; major disability by 18 to 24 months corrected age (aligned definition); retinopathy of prematurity requiring treatment; necrotising enterocolitis; blindness. Two authors (LA, RW) independently assessed the quality of the evidence for each of the outcomes above. The full author group further considered the 'Risk of bias' assessments and discussed these in detail at a NeOProM Collaborators meeting on 29 April 2016 in order to reach consensus. We considered evidence from randomised controlled trials as high quality but downgraded the evidence by one level for serious (or by two levels for very serious) limitations based upon the following: design (risk of bias), consistency across studies, directness of the evidence, precision of estimates and presence of publication bias. We used the GRADEpro GDT Guideline Development Tool to create a 'Summary of findings' table to report the quality of the evidence. The GRADE approach results in an assessment of the quality of a body of evidence of one of four grades:
• High: We are very confident that the true effect lies close to that of the estimate of the effect.
• Moderate: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
• Low: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
• Very low: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
Subgroup analysis and investigation of heterogeneity
The effect of the intervention (lower versus higher oxygen saturation targeting) may be different due to certain characteristics of either the infant or the way the intervention was delivered. If possible, we explored these effects in the following subgroup analyses. We limited subgroup analyses to the primary outcome (death or major disability), the individual components of the primary outcome (death, major disability), and two key secondary outcomes (necrotising enterocolitis, retinopathy of prematurity requiring treatment). All subgroup analyses were pre-specified before any meta-analyses of combined data were undertaken.
Sensitivity analysis
We planned sensitivity analyses for situations where this might affect the interpretation of significant results (for example, where there are risks of bias associated with the quality of some of the included trials or missing outcome data).
R E S U L T S Description of studies Results of the search
We searched using the search strategy outlined previously from 1940 to 11 April 2016 and identified 3412 potential published studies and 329 trial registration records. LA and BD screened the citations and abstracts of these 3741 records in duplicate for the initial search covering the period 1940 to 14 May 2014, and LA and PD screened these for the updated search covering the period from 1 January 2014 to 11 April 2016 (see Figure 1 ). There were no disagreements regarding study eligibility that required resolution.
Included studies
We identified five trials meeting the inclusion criteria of the review (n = 4965 infants) ( The inclusion criteria were similar between trials. All trials enrolled preterm infants of less than 28 weeks' gestation, with one specifying a minimum gestation of 24 weeks' (Vaucher 2012) and another 23 weeks' (Schmidt 2013). Three trials also required infants to be less than 24 hours old (Schmidt 2013; BOOST NZ 2014; BOOST-II Australia 2016), one required the infants to be less than 12 hours old (or less than 24 hours if outborn) (BOOST-II UK 2016), and one trial required infants to be enrolled by two hours of age (Vaucher 2012) . In all five trials the intervention and comparator were the same, i.e. lower oxygen saturation targeting (SpO 85% to 89%) versus higher oxygen saturation targeting (SpO 91% to 95%), although recommendations for alarm limit settings differed between trials (see Characteristics of included studies table).
Excluded studies
We assessed four studies (one published study, one conference proceeding, and two trial registration records) in full but excluded them as they were either not randomised trials or did not fulfil the other eligibility criteria for the interventions being compared, but this had not been clear from the title or abstract of the identified record (see the Characteristics of excluded studies table for the reasons for these exclusions). There were no other identified ongoing studies or studies awaiting clarification that were potentially eligible for inclusion.
Risk of bias in included studies
We assessed methodological quality using the criteria of Cochrane Neonatal and the findings are summarised in Figure 3 .
Incomplete outcome data
We assessed incomplete outcome data (attrition bias) as low risk of bias in all five trials. The primary outcome was a composite outcome of death or major disability by 18 to 24 months corrected for gestational age. Survival status was known for 97% to 100% of all infants in each trial. Major disability was defined as severe visual loss, deafness requiring hearing aids, cerebral palsy by various measures, or as a Bayley-III Developmental Assessment (BSID-III) cognitive score < 85 and/or language score < 85. There was variation between trials in the completeness of primary outcome data gathered according to the BSID-III assessments. By this measure between 79% and 96% had adequate data for the analysis of the composite primary outcome within the included trials (see Characteristics of included studies table). In two trials (Vaucher 2012 and Schmidt 2013, with 94% and 96% recovered data respectively), there was no imputation of missing data. In the three other trials various alternative measures of developmental status were substituted (BOOST NZ 2014; BOOST-II UK 2016; BOOST-II Australia 2016). With this qualification, all trials reported greater than 94% recovery of data for the primary analysis. These data, with protocol defined and alternative measures, were used in the definitions of the primary outcome and of major disabilities.
Selective reporting
We assessed selective reporting (reporting bias) as low risk in all five trials, with all trials reporting their pre-specified primary outcome and main secondary outcomes, and the trials identified any post hoc analyses in their trial reports.
Other potential sources of bias
Investigator concerns resulting from the significantly increased mortality risk with the lower SpO 2 target range in the SUPPORT Trial publication led to an unscheduled safety analysis when 1135 of the planned 1200 (95%) BOOST-II Australia and 973 of the planned 1200 (81%) BOOST-II UK infants had been recruited (BOOST-II Australia 2016; BOOST-II UK 2016). A decision was made to terminate recruitment in both the BOOST-II UK and BOOST-II Australia trials based on a pre-specified rule. There was an 8.5% excess in 36-week mortality in the low target group monitored with oximeters incorporating the revised calibration software (data pooled from both studies, P < 0.001 with a significant treatment by software subgroup interaction, P = 0.006) (Stenson 2011) . The early stopping of these two trials (with 95% and 81% of their final planned sample sizes at that point) raises the question of whether this overestimates treatment effect, and thus the risk of bias was categorised as 'unclear' for the BOOST-II UK and BOOST-II Australia trials. The other three trials were assessed as low risk of bias for this criterion.
Effects of interventions
See: Summary of findings for the main comparison Oxygen saturation targeting in preterm infants After considerable discussion between the review authors, we reached consensus regarding the quality of evidence assessments and data extraction from the five included trials.
Lower versus higher targeted oxygen saturations (no subgroups)
For the purpose of these analyses, we considered the lower target range group the intervention group and we considered the higher target range group the control group. The SUPPORT trial used a different Bayley-III cut point (< 70) and components (composite cognitive score only) as part of their definition of major disability compared with the other four trials (which used Bayley-III < 85 on either the composite cognitive or language scores). The SUPPORT trial provided unpublished outcome data using the same Bayley-III cut point and components for inclusion in this review in order to better align the definitions of major disability across all five trials. For the outcomes where these data were used, we used the term 'aligned definition'. However, the definition of major disability was not 'fully' aligned as each trial used slightly different methods for assigning an outcome of major disability. The term 'trialist defined' used throughout this review indicates analyses that used data as published in the trial reports. For the two outcomes where these data are relevant ('death or major disability' and 'major disability'), both the 'aligned definition' and 'trialist defined' versions are presented. However, our primary analyses are based on the meta-analyses of updated data, using the aligned definition of major disability. The SUPPORT trial also provided unpublished data for inclusion in this review to align the definition of 'retinopathy of prematurity requiring treatment' across all trials. We graded the quality of evidence for outcomes as high (low risk of bias, low inconsistency, no indirectness, low imprecision, and low risk of reporting bias) unless otherwise stated below.
Primary outcome
Death or major disability by 18 to 24 months corrected age (aligned definition) (outcome 1.1)
Using the aligned definition of this outcome, there was no significant difference between the groups in the incidence of death or major disability by 18 to 24 months corrected age (typical risk ratio (RR) 1.04, 95% confidence interval (CI) 0.98 to 1.10; typical risk difference (RD) 0.02, 95% CI -0.01 to 0.05; 5 trials, 4754 infants; I² = 27%) (high-quality evidence) (Analysis 1.1).
Death or major disability by 18 to 24 months corrected age (trialist defined) (outcome 1.2)
The meta-analysis showed a statistically significant increased risk of death or major disability at 18 to 24 months corrected age for the lower target group when using the trialists' own definitions of major disability (typical RR 1.07, 95% CI 1.00 to 1.14; typical RD 0.03, 95% CI 0.00 to 0.06; 5 trials, 4751 infants; I² = 1%) (Analysis 1.2).
Secondary outcomes
Death to 18 to 24 months corrected age (outcome 1.3)
The meta-analysis showed a statistically significant increased risk of death at 18 to 24 months corrected age for the lower target group (typical RR 1.16, 95% CI 1.03 to 1.31; typical RD 0.03, 95% CI 0.01 to 0.05; 5 trials, 4873 infants; I² = 0%) (highquality evidence) (Analysis 1.3). The number needed to treat for an additional harmful outcome (NNTH) with lower targeting to result in one additional death by 18 to 24 months corrected age is 31 (95% CI 16 to 168).
Major disability by 18 to 24 months corrected age (aligned definition) (outcome 1.4)
There was no significant difference between the groups in the incidence of major disability by 18 to 24 months corrected age when using the aligned definition of major disability (see Outcome 1.2 above) across trials (typical RR 1.01, 95% CI 0.93 to 1.09; 5 trials, 3867 infants; I² = 22%) (high-quality evidence) (Analysis 1.4).
Major disability by 18 to 24 months corrected age (trialist defined) (outcome 1.5)
There was no significant difference between the groups in the incidence of major disability by 18 to 24 months corrected age when using the trialists' own definitions of major disability (typical RR 1.04, 95% CI 0.94 to 1.14; 5 trials, 3864 infants; I² = 0%) (Analysis 1.5).
Death to discharge (outcome 1.6)
The meta-analysis showed a statistically significant increased risk of death before discharge for the lower target group (typical RR 1.16, 95% CI 1.03 to 1.31; typical RD 0.03, 95% CI 0.00 to 0.05; 5 trials, 4958 infants; I² = 0%) (Analysis 1.6). The NNTH with lower targeting to result in one additional death to discharge is 34 (95% CI 17 to 180).
Severe retinopathy of prematurity (ROP) or retinal therapy (trialists defined) (outcome 1.7)
The meta-analysis showed a statistically significant reduced risk of severe ROP or retinal therapy for the lower target group (typical RR 0.72, 95% CI 0.61 to 0.85; typical RD -0.04, 95% CI -0.06 to -0.02; 5 trials, 4089 infants; I² = 69%) (moderate-quality evidence) (Analysis 1.7). We rated the quality of evidence for this outcome as moderate due to inconsistency (moderate heterogeneity). The number needed to treat for an additional beneficial outcome (NNTB) with lower oxygen targeting to prevent one additional case of severe ROP or retinal therapy is 34 (95% CI 21 to 63).
Patent ductus arteriosus requiring medical or surgical treatment (outcome 1.8)
There was no significant difference between the groups in the incidence of patent ductus arteriosus requiring medical or surgical treatment (typical RR 1.00, 95% CI 0.95 to 1.06; 5 trials, 4928 infants; I² = 0%) (Analysis 1.8).
Necrotising enterocolitis (outcome 1.9)
Three trials (BOOST Australia, NZ, and UK) used a definition of 'necrotising enterocolitis requiring surgery or leading to death' for this outcome. The other two trials used either a modified Bell's staging (SUPPORT) or surgical or X-ray diagnoses (COT) to define this outcome. The meta-analysis showed a statistically significant increased risk of necrotising enterocolitis for the lower target group (typical RR 1.24, 95% CI 1.05 to 1.47; typical RD 0.02, 95% CI 0.01 to 0.04; 5 trials, 4929 infants; I² = 0%) (high-quality evidence) (Analysis 1.9). The NNTH with lower targeting to result in one additional case of necrotising enterocolitis is 37 (95% CI 19 to 178).
Cerebral palsy with Gross Motor Functioning Classification System (GMFCS) level 2 or higher at 18 to 24 months corrected age (outcome 1.10)
There was no significant difference between the groups in the incidence of cerebral palsy with GMFCS level 2 or higher at 18 to 24 months corrected age (typical RR 1.02, 95% CI 0.79 to 1.32; 5 trials, 3877 infants; I² = 20%) (Analysis 1.10).
Blindness (outcome 1.11)
There was no significant difference between the groups in the incidence of blindness (typical RR 1.13, 95% CI 0.65 to 1.97; 5 trials, 3875 infants; I² = 0%) (Analysis 1.11). We rated the quality of evidence for this outcome as moderate for imprecision due to low event rates.
Severe hearing loss (outcome 1.12)
There was no significant difference between the groups in the incidence of severe hearing loss (typical RR 1.02, 95% CI 0.73 to 1.43; 5 trials, 3869 infants; I² = 0%) (Analysis 1.12). We rated the quality of evidence for this outcome as moderate for imprecision due to low event rates.
Proportion of infants re-admitted to hospital up to 18 to 24 months corrected age (outcome 1.13)
There was no significant difference between the groups in the proportion of infants re-admitted to hospital up to 18 to 24 months corrected age (RR 1.08, 95% CI 0.93 to 1.26; 1 trial, 295 infants; I² not applicable) (Analysis 1.13). We rated the quality of evidence for this outcome as moderate for imprecision as data were available from only one trial.
Weight (grams) at discharge home (outcome 1.14)
There was no significant difference between the groups in the weight (grams) of infants at discharge home (mean difference (MD) -52.00, 95% CI -214.25 to 110.25; P = 0.53; 1 trial, 295 infants; I² not applicable) (Analysis 1.14). We rated the quality of evidence for this outcome as moderate for imprecision as data were available from only one trial.
Weight (kilograms) at 18 or 24 months corrected age (outcome 1.15)
There was no significant difference between the groups in the weight (grams) of infants at discharge home (MD 0.80, 95% CI -0.24 to 1.84; 1 trial, 280 infants; I² not applicable) (Analysis 1.15). We rated the quality of evidence for this outcome as moderate for imprecision as data were available from only one trial.
Days of endotracheal intubation (outcome 1.16)
There was no significant difference between the groups in days of endotracheal intubation (MD 0.28, 95% CI -1.16 to 1.72; 2 trials, 1386 infants; I² = 0%) (Analysis 1.16).
Days of continuous positive airway pressure (CPAP) (outcome 1.17)
There was no significant difference between the groups in days of CPAP (MD -0.04, 95% CI -1.38 to 1.30; 3 studies, 2526 infants; I² = 0%) (Analysis 1.17).
Days of supplemental oxygen (outcome 1.18)
The meta-analysis showed a statistically significant reduction in days of supplemental oxygen for the lower target group (MD -8.78, 95% CI -12.02 to -5.54; P < 0.00001; 3 trials, 2507 infants; I² = 4%) (Analysis 1.18).
Supplemental oxygen requirement at 36 weeks postmenstrual age (outcome 1.19)
This outcome was determined using a physiologic test in the Vaucher 2012 and BOOST-II UK 2016 trials while the other three trials determined the need for supplemental oxygen at 36 weeks postmenstrual age using the infant's assigned study oximeter. The meta-analysis showed a statistically significant reduced risk of supplemental oxygen requirement at 36 weeks postmenstrual age for the lower target group (typical RR 0.87, 95% CI 0.81 to 0.94; typical RD -0.06, 95% CI -0.09 to -0.03; 5 trials, 4175 infants; I² = 44%) (Analysis 1.19). We rated the quality of evidence for this outcome as moderate due to inconsistency (moderate heterogeneity). The NNTB with lower oxygen targeting to prevent one additional infant receiving supplemental oxygen at 36 weeks postmenstrual age is 20 (95% CI 14 to 44).
Days on home oxygen (outcome 1.20)
For the infants who went home on supplemental oxygen (n = 237), there was no significant difference between the groups in the days of home oxygen (MD -24.17, 95% CI -57.99 to 9.66; P = 0.16; 2 trials, 237 infants; I² = 61%) (Analysis 1.20). We rated the quality of evidence for this outcome as low due to inconsistency (moderate heterogeneity) and imprecision.
Quantitative Bayley III scores (Composite Cognitive Score (CCS)) (outcome 1.21)
There was no significant difference between the groups in quantitative Bayley III scores (Composite Cognitive Score (CCS)) (MD 0.55, 95% CI -0.91 to 2.00; P = 0.46; 2 trials, 1892 infants; I² = 0%) (Analysis 1.21).
Quantitative Bayley III scores (Composite Language Score (CLS)) (outcome 1.22)
There was no significant difference between the groups in quantitative Bayley III scores (Composite Language Score (CLS)) (MD 0.20, 95% CI -2.03 to 2.43; 1 trial, 903 infants; P = 0.86; I² not applicable) (Analysis 1.22). We rated the quality of evidence for this outcome as moderate for imprecision as data were available from only one trial.
Lower versus higher targeted oxygen saturations (primary outcome, subgrouped by gestational age)
Death or major disability by 18 to 24 months corrected age (trialist defined) (outcome 2.1)
There was no statistically significant difference in the incidence of death or major disability by 18 to 24 months corrected age (trialist defined) in the subgroup of infants born at < 26 weeks' gestation (RR 1.09, 95% CI 0.89 to 1.32; 1 trial, 537 infants; I² not applicable) compared with infants born at ≥ 26 weeks' gestation (RR 1.17, 95% CI 0.86 to 1.60; 1 trial, 697 infants; I² not applicable): test for subgroup difference P = 0.69. We rated the quality of evidence for this outcome as moderate for imprecision as data were available from only one trial (Analysis 2.1).
Lower versus higher targeted oxygen saturations (primary outcome, subgrouped by sex)
Death or major disability by 18 to 24 months corrected age (trialist defined) (outcome 3.1)
There was no statistically significant difference in the incidence of death or major disability by 18 to 24 months corrected age (trialist defined) in the subgroup of male infants (RR 1.13, 95% CI 0.96 to 1.33; 1 trial, 503 infants; I² not applicable) compared with female infants (RR 1.07, 95% CI 0.87 to 1.31; 1 trial, 438 infants; I² not applicable): test for subgroup difference P = 0.66. We rated the quality of evidence for this outcome as moderate for imprecision as data were available from only one trial (Analysis 3.1).
Lower versus higher targeted oxygen saturations (primary outcome, subgrouped by multiples)
Death or major disability by 18 to 24 months corrected age (trialist defined) (outcome 4.1)
There was no statistically significant difference in the incidence of death or major disability by 18 to 24 months corrected age (trialist defined) in the subgroup of singleton infants (RR 1.10, 95% CI 0.94 to 1.29; 1 trial, 670 infants; I² not applicable) compared with infants from multiple births (RR 1.11, 95% CI 0.88 to 1.39; 1 trial, 271 infants; I² not applicable): test for subgroup difference P = 0.94. We rated the quality of evidence for this outcome as moderate for imprecision as data were available from only one trial (Analysis 4.1).
Lower versus higher targeted oxygen saturations (primary outcome, subgrouped by oximeter calibration software)
Death or major disability by 18 to 24 months corrected age (aligned definition) (outcome 5.1)
There was no statistically significant difference in the incidence of death or major disability by 18 to 24 months corrected age (aligned definition) in the subgroup of infants who used the original oximeter calibration algorithm (typical RR 1.00, 95% CI 0.94 to 1.07; 5 trials, 3003 infants; I² = 0%) compared with the infants who used the revised algorithm (typical RR 1.13, 95% CI 1.02 to 1.24; 3 trials, 1681 infants; I² = 0%): test for subgroup difference P = 0.06 (Analysis 5.1).
Death or major disability by 18 to 24 months corrected age (trialist defined) (outcome 5.2)
There was no statistically significant difference in the incidence of death or major disability by 18 to 24 months corrected age (trialist defined) in the subgroup of infants who used the original oximeter calibration algorithm (typical RR 1.04, 95% CI 0.95 to 1.13; 5 trials, 3000 infants; I² = 0%) compared with infants who used the revised oximeter calibration algorithm (typical RR 1.13, 95% CI 1.02 to 1.24; 3 trials, 1681 infants; I² = 0%): test for subgroup difference P = 0.24 (Analysis 5.2).
Lower versus higher targeted oxygen saturations (secondary outcomes, subgrouped by oximeter calibration software)
Death by 18 to 24 months corrected age (outcome 6.1)
There was a statistically significant difference in the incidence of death by 18 to 24 months corrected age in the subgroup of infants who used the original oximeter calibration algorithm (typical RR 1.05, 95% CI 0.91 to 1.22; 5 trials, 3087 infants; I² = 5%) compared with infants who used the revised oximeter calibration algorithm (typical RR 1.38, 95% CI 1.13 to 1.68; 3 trials, 1716 infants; I² = 0%): test for subgroup difference P = 0.03 (Analysis 6.1).
Major disability by 18 to 24 months corrected age (aligned definition) (outcome 6.2)
There was no statistically significant difference in the incidence of major disability by 18 to 24 months corrected age (aligned definition) in the subgroup of infants who used the original oximeter calibration algorithm (typical RR 0.99, 95% CI 0.90 to 1.09; 5 trials, 2529 infants; I² = 40%) compared with infants who used the revised oximeter calibration algorithm (typical RR 1.05, 95% CI 0.91 to 1.22; 3 trials, 1438 infants; I² = 0%): test for subgroup difference P = 0.49 (Analysis 6.2).
Major disability by 18 to 24 months corrected age (trialist defined) (outcome 6.3)
There was no statistically significant difference in the incidence of major disability by 18 to 24 months corrected age (trialist defined) in the subgroup of infants who used the original oximeter calibration algorithm (typical RR 1.02, 95% CI 0.89 to 1.17; 5 trials, 2526 infants; I² = 30%) compared with infants who used the revised oximeter calibration algorithm (typical RR 1.05, 95% CI 0.91 to 1.22; 3 trials, 1438 infants; I² = 0%): test for subgroup difference P = 0.78 (Analysis 6.3).
Death to discharge (outcome 6.4)
There was a statistically significant difference in the incidence of death to discharge in the subgroup of infants who used the original oximeter calibration algorithm (typical RR 1.06, 95% CI 0.90 to 1.26; 4 trials, 2575 infants; I² = 37%) compared with infants who used the revised oximeter calibration algorithm (typical RR 1.45, 95% CI 1.15 to 1.84; 2 trials, 1182 infants; I² = 0%): test for subgroup difference P = 0.04 (Analysis 6.4).
Severe retinopathy of prematurity or retinal therapy (trialist defined) (outcome 6.5)
There was no statistically significant difference in the incidence of severe retinopathy of prematurity or retinal therapy in the subgroup of infants who used the original oximeter calibration algorithm (typical RR 0.67, 95% CI 0.53 to 0.84; 4 trials, 2085 infants; I² = 67%) compared with infants who used the revised oximeter calibration algorithm (typical RR 0.77, 95% CI 0.56 to 1.05; 2 trials, 988 infants; I² = 55%): test for subgroup difference P = 0.47 (Analysis 6.5).
Lower versus higher targeted oxygen saturations (secondary outcomes, subgrouped by gestational age)
Death by 18 to 24 months corrected age (outcome 7.1) There was no statistically significant difference in the incidence of death by 18 to 24 months corrected age in the subgroup of infants born at < 26 weeks' gestation (RR 1.22, 95% CI 0.95 to 1.57; 1 trial, 550 infants; I² = not applicable) compared with infants born at ≥ 26 weeks' gestation (RR 1.25, 95% CI 0.84 to 1.86; 1 trial, 731 infants; I² = not applicable): test for subgroup difference P = 0.91. We rated the quality of evidence for this outcome as moderate for imprecision as data were available from only one trial (Analysis 7.1).
Major disability by 18 to 24 months corrected age (trialist defined) (outcome 7.2)
There was no statistically significant difference in the incidence of major disability by 18 to 24 months corrected age in the subgroup of infants born at < 26 weeks' gestation (RR 0.84, 95% CI 0.52 to 1.37; 1 trial, 367 infants; I² = not applicable) compared with infants born at ≥ 26 weeks' gestation (RR 1.07, 95% CI 0.59 to 1.93; 1 trial, 609 infants; I² = not applicable): test for subgroup difference P = 0.54. We rated the quality of evidence for this outcome as moderate for imprecision as data were available from only one trial (Analysis 7.2).
D I S C U S S I O N
Summary of main results
When compared to targeting a higher oxygen saturation range (SpO 91% to 95%) from soon after birth in extremely preterm infants, targeting a lower oxygen saturation range (SpO 85% to 89%) had no significant effect on the primary composite outcome of death or major disability (using an aligned definition) (P = 0.18), but significantly increased the incidence of death at 18 to 24 months corrected age (P = 0.01), death before hospital discharge (P = 0.02), and necrotising enterocolitis (P = 0.01). Targeting the lower range significantly decreased the rate of severe or treated retinopathy of prematurity (ROP) (P = 0.004) and supplemental oxygen use at 36 weeks postmenstrual age (P = 0.0002), but had no significant effect on blindness (P = 0.65), patent ductus arteriosus requiring treatment (P = 0.87), or major disability (when an aligned definition across trials was used) at 18 to 24 months corrected age (P = 0.80). Subgroup analyses of major outcomes by oximeter calibration software (original versus revised) showed a statistically significant difference in death by 18 to 24 months corrected age: original algorithm (P = 0.52) versus revised algorithm (P = 0.001) (test for subgroup difference P = 0.03). A similar result was seen for death before hospital discharge (test for subgroup difference P = 0.04). There were no other participant or intervention characteristics within the pre-specified subgroup analyses that showed significant differences in the treatment effect, although data for many are not yet currently available from the published trials. The five trials included in this review were prospectively planned to be similar with regards to the enrolled participants, the interventions compared, and the outcomes measured and they were designed to be included in a meta-analysis once the individual trials were completed. As would thus be expected, the heterogeneity seen across the trials for most outcomes was low. Similarly there was an overall low risk of bias across all five trials. In the meta-analysis the combined sample size of 4965 provides high-quality, robust evidence for important outcomes with regards to oxygen saturation targeting in extremely preterm infants.
Overall completeness and applicability of evidence
Data were available and complete from all five included trials for the primary outcome (death or major disability at 18 to 24 months corrected age), and the components of the primary outcome: death, major disability, cerebral palsy, blindness, and severe hearing loss, as well as other important neonatal outcomes including death before hospital discharge, severe ROP, patent ductus arteriosus requiring treatment, and necrotising enterocolitis. Upon request, trialists provided unpublished data (SUPPORT for retinopathy requiring treatment and major disability with definition aligned with the other trials, and COT for death before discharge) to improve the completeness of the included data for the major outcomes. Other secondary outcomes (1.13 to 1.23) and subgroup analyses (small for gestational age, multiples, antenatal steroids, inborn status) data are either incomplete or not available from the current trial publications. The included trials are all members of the NeOProM Collaboration, which is currently collating and analysing the individual participant data (IPD) from all five trials, including data for the outcomes pre-specified, but not yet available in this review. It is anticipated that once the NeOProM analyses have been published, this review will be updated with the additional information. Supplemental oxygen delivery and monitoring in extremely preterm infants in the first days/weeks of life can be particularly challenging. How well a target oxygen saturation range is maintained is dependent on many factors including infant stability, alarm limit settings and compliance with these settings, pulse oximeter properties (e.g. averaging times, alarm trigger delay times), and nursing staff ratios and experience levels, all of which can contribute to alarm burden/fatigue. It should be noted that the trials included in this review did not specifically assess the effects of actual target ranges achieved, they assessed the intention to target one of two oxygen saturation ranges. It should also be re-iterated that the included trials assessed the effect of different targeting policies, not the effects of different alarm settings. Future technologies, such as automated oxygen titration, and more complex alarm strategies, such as variations in alarm escalation regimes and cell phone notifications, may all contribute to how well a desired target range is maintained for an individual infant. However, until we have better monitoring systems that accurately provide information regarding tissue oxygenation, we will need to continue to rely on thorough review of oxygen saturation histograms to better target oxygen saturation in extremely preterm infants.
The reasons for the difference in mortality seen when oximeters with the original calibration software, compared to the revised software, were used cannot be explained simply with the currently available data. Further exploration of oximeter saturation data from the five NeOProM trials will be needed to assess whether this difference was due to the change in oximeter software resulting in more effective targeting of SpO , whether trial centres became more effective at targeting SpO over time, or whether there are other explanations for the differences seen. Until further analyses are undertaken, the best estimate of the effects of different target ranges should be focused on the combined results from all trials.
Quality of the evidence
Overall, we assessed all five included trials as being at low risk of bias (see Characteristics of included studies) as all employed random sequence generation, had adequate allocation concealment, were blinded to participants, personnel and outcome assessors, had low levels of missing data, and have (or will have, within the NeOProM analyses) reported all pre-specified outcomes (low risk of reporting bias). Although data are currently unavailable for some of the secondary and subgroup analyses, we have not downgraded these outcomes for 'missingness' as they are known to be available and will be included in updated versions of this review once the NeOProM analyses are available. As noted previously, this prospectively planned meta-analysis has low levels of statistical heterogeneity (inconsistency) for most outcomes. The 'severe retinopathy of prematurity or retinal therapy' outcome had a moderate level of heterogeneity (I² = 69%), which resulted from the substantially larger treatment effect of lower targeting on this outcome in the SUPPORT trial. Reasons for the larger treatment effect for this outcome seen in the SUPPORT trial need to be further explored, possibly by examining 'achieved' (rather than 'intended') saturation patterns across trials. The other outcome that had a moderate level of heterogeneity (I² = 44%) was 'supplemental oxygen at 36 weeks postmenstrual age'. There were differences between the trials in how the need for supplemental oxygen at 36 weeks was assessed, with two trials (SUPPORT and BOOST-II UK) using a physiologic test to determine this need, while the other three trials did not use such a test. The outcomes of blindness (1.11) and severe hearing loss (1.12) had low event rates (43 and 131 events respectively from 3870 infants) so while there was no heterogeneity seen for these outcomes (I² = 0% for both), we downgraded both for imprecision due to the resulting wide 95% confidence intervals. Despite being well planned and conducted, all five trials each only achieved a 2% to 3% difference in median oxygen saturations between the two treatment groups. There was also variability (clinical heterogeneity) between trials in the oximeter alarm settings (see 
Characteristics of included studies table) and in achieved SpO
distributions.
All five trials directly assessed the same comparisons (SpO 85% to 89% versus 91% to 95%) and the combined sample size of over 3800 for all the main outcomes resulted in the quality of evidence remaining graded as high with regards to the indirectness and imprecision criteria. Given the above quality assessments, for the main outcomes (primary outcomes 1.1. and 1.2 and key secondary outcomes 1.3 to 1.12) more evidence is unlikely to change our confidence in the estimates of the effects, and these outcomes are thus graded as high-quality overall. Other secondary outcomes (1.13 to 1.23) and subgroup analyses (small for gestational age, multiples, antenatal steroids, inborn status) data are either incomplete or not available from the current trial publications resulting in grading the evidence as moderate for these outcomes at present. Further planned evidence from the NeOProM Collaboration will likely change this assessment of moderate quality for these outcomes in the near future.
Potential biases in the review process
The inclusion of representatives from the five included trials, the NeOProM Collaboration, and an independent author in the review team meant that there was considerable debate, discussion, and difference of opinion regarding many issues covered within this review. Where consensus could not be reached within the author team regarding the interpretation of the review's findings using the methods outlined, we have included the differing views.
Agreements and disagreements with other studies or reviews
The data included in this Cochrane Review allow the most complete meta-analysis of the five NeOProM trials published to date, including unpublished information sourced directly from the trialists for the 'aligned' definition of major disability-related outcomes (Analysis 1.1; Analysis 1.4) and treated ROP (Analysis 1.7), thereby superceding the previous meta-analyses by Manja 2017 , Manja 2015 , Saugstad 2014 , Fang 2016 and Stenson 2016 . This review was undertaken with direct input from the investigators whose trials were included, and involved extensive discussion and consultation. An author independent of the trialists and the NeOProM Collaboration (MV) provided additional input and was available to resolve disagreements when necessary. The resulting Characteristics of included studies table, including the 'Risk of bias' assessments, are thus based on detailed information sourced directly from the trialists, which was not available to the authors of the other published reviews. These assessments of the quality of evidence (high to moderate) and strength of recommendations (GRADE criteria) thus differ from those published by Manja 2015 (moderate to low).
A U T H O R S ' C O N C L U S I O N S Implications for practice
When using an aligned definition for major disability, this metaanalysis of five randomised trials found no significant difference in the primary composite outcome of death or major disability in extremely preterm infants when targeting a lower (SpO 85% to 89%) versus higher (SpO 91% to 95%) oxygen saturation range. Compared with a higher target range, a lower target range significantly increased the incidence of death (at both discharge and 18 to 24 months corrected age) and necrotising enterocolitis. Conversely, targeting the lower range significantly decreased the incidence of severe or treated retinopathy of prematurity. There were no significant differences between the two treatment groups for major disability including blindness, severe hearing loss, cerebral palsy or other important neonatal morbidities. A pre-specified subgroup analysis of major outcomes by type of oximeter calibration software (original versus revised) found a significant difference in the treatment effect between the two software types for death, with a significantly larger treatment effect seen for those infants using the revised calibration software. There were no other significant differences in treatment effect in any of the pre-specified subgroup analyses, although data for many of these analyses are not available within the published trial reports.
The size of the observed treatment effects found in this metaanalysis give estimates that for every 31 to 40 extremely preterm infants targeted at a lower oxygen range, on average there would be one additional death and one additional case of necrotising enterocolitis, but there would be one less infant with severe/treated ROP, and eight less days of oxygen exposure per patient. The treatment effect estimates found in this review show the relative effects of the different target ranges on outcomes. The number needed to treat for an additional beneficial/harmful outcome (NNTB/ NNTH) estimates included in this review are based on the absolute risk reductions found within the included trials. Whilst the baseline risks for each of these outcomes may differ in different settings, and thus trade-offs between the benefits and harms of the different target ranges can be assessed at a local level (Schmidt 2014) , the combined data included in this review constitute the largest dataset as yet compiled to address this clinical question. As such, these results provide important information for clinicians, researchers, parents, and other stakeholders to make judgements regarding the choice of oxygen saturation targets. It should, however, be noted that the findings of this meta-analysis should not be extrapolated to oxygen saturation ranges, or practice settings, outside those tested within the included trials. Similarly, data from this review do not provide evidence of an ability to personalise oxygen saturation targets for individual infants. that a targeted oxygen saturation range of 90% to 95% may be safer than 85% to 89%" (Cummings 2016). The results from this review concur with this conclusion.
Implications for research
Further meta-analyses using individual participants from the NeOProM Collaboration will provide data for the remaining secondary outcomes and planned subgroup analyses.
More detailed examination of the included trials' pulse oximetry data (either individually or collectively) will be important to ascertain why such a small change in the target range (of approximately 2% to 3% saturation points) produced the significant differences in important outcomes, such as death and necrotising enterocolitis, which were seen. This could include investigation of potential effect modifying factors such as the proportion of time spent at lower SpO levels, or other combinations of participant-and intervention-level factors. The implications for nursing practice when implementing these findings in practice may warrant further study, including the potential for new technologies such as automated inspired oxygen adjustment, the effects of nursing staff ratios, and alarm policies.
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C H A R A C T E R I S T I C S O F S T U D I E S Characteristics of included studies [ordered by year of study]
Vaucher 2012
Methods Randomised, multicentre (USA) trial with a 2-by-2 factorial design Participants 1316 infants born between 24 weeks 0 days and 27 weeks 6 days of gestation. Infants were enrolled prior to birth and were thus all inborn at a trial centre. Interventions Infants were monitored with target ranges of oxygen saturation of 85% to 89% or 91% to 95% using oximeters with concealed saturation offsets of +3% in actual range 85% to 92% (low target) and -3% in range 88% to 95% (high target), with true readings displayed 84% and below and 96% and above (see Figure 4 ). Caregivers were asked to adjust the concentration of oxygen to maintain displayed saturations between 88% and 92% when the infant was receiving supplemental oxygen. Alarms were suggested to be set so that an alarm would sound at displayed saturation values of 85% and 95%, but they could be changed for individual patients. Infants were also randomly assigned to continuous positive airway pressure or intubation and surfactant. Intervention was initiated within 2 hours of birth and continued until 36 weeks of postmenstrual age or until the infant was breathing ambient air, whichever occurred first. Infants who were returned to supplemental oxygen were reassigned to the study oximeter. All infants in this trial were managed with oximeters using the original calibration software Outcomes Co-primary outcomes: survival at discharge from hospital without severe ROP (threshold ROP and/or the need for surgical intervention) assessed until diagnosis or resolution; and death or survival with neurodevelopmental impairment at 18 to 22 months corrected age Neurodevelopmental impairment was defined as having any of the following: * BSID-III cognitive or language score < 70 * GMFCS level 2 or higher * No participants were excluded after randomisation. All outcome analyses followed the principle of intention-to-treat. The follow-up rate and the mean corrected age at neurodevelopmental assessment were similar for all treatment groups (in the 2-by-2 factorial design)
Selective reporting (reporting bias) Low risk The predetermined sample size of 1310 infants was achieved. The original study protocol specified a composite primary outcome of death before 36 weeks of post- menstrual age or severe ROP, but this was changed to death before discharge or severe ROP before any data analyses were performed. All other outcomes pre-specified in the registration record were reported, including assessment of the need for oxygen at 36 weeks postmenstrual age and safety outcomes
Other bias
Low risk The baseline characteristics of the 2 treatment groups were similar Interventions Infants were monitored with target ranges of oxygen saturation of 85% to 89% or 91% to 95% using oximeters with concealed saturation offsets of +3% in actual range 85% to 92% (low target) and -3% in range 88% to 95% (high target), with true readings displayed 84% and below and 96% and above (see Figure 4 ). Caregivers were asked to adjust the concentration of oxygen to maintain displayed saturations between 88% and 92% when the infant was receiving supplemental oxygen. Alarms were set so that an alarm would sound at displayed saturation values of 86% and 94%. Intervention was initiated within 24 hours of birth and continued until 36 weeks of postmenstrual age irrespective of supplemental oxygen therapy, and until 40 weeks in infants receiving oxygen therapy at 35 weeks. The oximeters used in this trial were modified with a revised calibration software in early 2009. 47% of infants in this trial were managed with oximeters using the original calibration software, 47% with oximeters using the revised calibration software, and 6% were exposed to both Outcomes Primary outcome: death or survival with major disability at 18 to 21 months corrected age.
Major disability was defined as having any of the following: * Cognitive score < 85 or language score < 85 on BSID-III * Severe visual loss * Cerebral palsy with GMFCS level 2 or higher * Deafness requiring hearing aids Secondary outcomes: retinopathy of prematurity, brain injury, patent ductus arterious, necrotising enterocolitis, bronchopulmonary dysplasia, duration of use of positive airway pressure and supplemental oxygen, hospital re-admissions for respiratory disease, chronic use of respiratory medications, and mean composite cognitive, language and motor scores Low risk A computer-generated randomisation scheme at a remote co-ordinating centre assigned the infants to treatment groups in a 1:1 ratio. Randomisation was stratified by study centre and balanced within randomly sized blocks of 2 or 4 patients. Siblings within multiple births were randomised individually Allocation concealment (selection bias)
Low risk Study oximeters were labelled with sequential participant numbers according to the randomisation scheme. The allocation remained unknown to the members of the clinical and research teams and all staff at the co-ordinating centre
Blinding of participants and personnel (performance bias) All outcomes
Low risk Blinding was maintained by oximeter design. There is evidence that the algorithm used for blinding caused a difference in nursing behaviour with high versus low oximeters, which reduced separation and which could have resulted in detection or co-intervention bias Blinding of outcome assessment (detection bias) All outcomes
Low risk Parents and assessors were unaware of allocation.
Incomplete outcome data (attrition bias) All outcomes Low risk Of the 1201 infants enrolled, 1147 (95. 5%) had adequate data for the analysis of the composite primary outcome at 18 to 21 months corrected age 39 infants were of unknown status (17 low target group, 22 high target group) and 15 had incomplete or no follow-up (7 low target group, 8 high target group). If Bayley scores were missing, children were excluded from the primary outcome analysis No participants were excluded after randomisation. All outcome analyses followed the principle of intention-to-treat. The fol-low-up rate and the mean corrected age at neurodevelopmental assessment were similar for both treatment groups Selective reporting (reporting bias) Low risk The predetermined sample size of 1201 infants was achieved. All outcomes pre-specified in the registration record were reported
Other bias Low risk There were imbalances in surfactant administration and in oxygen therapy before randomisation. Otherwise the baseline characteristics were similar in both groups
BOOST NZ 2014
Methods Randomised, multicentre (New Zealand) trial. Interventions Infants were monitored with target ranges of oxygen saturation of 85% to 89% or 91% to 95% using oximeters with concealed saturation offsets of +3% in actual range 85% to 92% (low target) and -3% in range 88% to 95% (high target), with true readings displayed 84% and below and 96% and above (see Figure 4 ). Caregivers were asked to adjust the concentration of oxygen to maintain displayed saturations between 88% and 92% when the infant was receiving supplemental oxygen. Alarm limits were recommended (but not mandated) to be set so that an alarm would sound at displayed saturation values of 87% and 93%. Intervention was initiated within 24 hours of birth, continued for at least two weeks and was discontinued when infants no longer required oxygen (pre-specified definition) or otherwise at 36 weeks. All infants in this trial were managed with oximeters using the original calibration software Outcomes Primary outcome: death or survival with major disability at 24 months corrected age. Major disability was defined as having any of the following: * Cognitive score < 85 or language score < 85 on BSID-III, or MDI < 70 on the BSID-II assessment * Severe visual loss * Cerebral palsy defined as GMFCS level 2 or higher * Deafness requiring hearing aids In 33 infants where Bayley scores were unavailable and there were no other events defining major disability, an alternative definition of disability (use of < 10 words) was used Secondary outcomes: severe ROP (≥ stage 3, or retinal surgery), oxygen dependency or respiratory support at 36 weeks' gestational age, days of continuous positive airway pressure, days of endotracheal intubation, days of oxygenation in both hospital and days at home, a patent ductus arteriosus diagnosed by echocardiography and requiring treatment, necrotising enterocolitis requiring surgery or a cause of death, weight at 2 the principle of intention-to-treat. The follow-up rate and the mean corrected age at neurodevelopmental assessment were similar for both treatment groups Selective reporting (reporting bias) Low risk The predetermined sample size of 320 infants was exceeded, with a final sample size of 340 being achieved. All outcomes prespecified in the registration record were reported
Other bias Low risk The baseline characteristics of the 2 treatment groups were similar
BOOST-II Australia 2016
Methods Randomised, multicentre (Australia) trial. Interventions Infants were monitored with target ranges of oxygen saturation of 85% to 89% or 91% to 95% using oximeters with concealed saturation offsets of +3% in actual range 85% to 92% (low target) and -3% in range 88% to 95% (high target), with true readings displayed 84% and below and 96% and above (see Figure 4 ). Caregivers were asked to adjust the concentration of oxygen to maintain displayed saturations between 88% and 92% when the infant was receiving supplemental oxygen. Alarm limits were recommended to be set so that an alarm would sound at displayed saturation values of 86% and 94%. Intervention was initiated within 24 hours of birth and discontinued when infants no longer required oxygen (pre-specified definition) or otherwise at 36 weeks. Infants who were returned to supplemental oxygen were reassigned to the study oximeter. The oximeters used in this trial were modified with a revised calibration algorithm in early 2009. 62% of infants in this trial were managed with oximeters with the original calibration algorithm and 38% with oximeters using the revised calibration algorithm Outcomes Primary outcome: death or survival with major disability at 24 months corrected age. Major disability was defined as having any of the following: * Cognitive score < 85 or language score < 85 on BSID-III * Severe visual loss * Cerebral palsy with inability to walk at 2 years corrected age * Deafness requiring hearing aids In 85 infants where Bayley scores were unavailable and there were no other events defining major disability, an alternative definition of disability (use of < 10 words, delayed development < 12 months, other severe impairment) was used Secondary outcomes: death at discharge, death at 36 weeks' postmenstrual age, treated retinopathy of prematurity, necrotising enterocolitis requiring surgery or leading to death, get group, 4 high target group) and 26 had incomplete or no follow-up (11 low target group, 15 high target group). When Bayley III scores were missing, alternative measures of disability were used, including Bayley II scales, paediatric health status assessment, or a Short Health Status Questionnaire collected via phone call to parents or a GP visit (n = 176 children). If none of these data were available, the primary endpoint was considered missing No participants were excluded after randomisation. All outcome analyses followed the principle of intention-to-treat. The follow-up rate and the mean corrected age at neurodevelopmental assessment were similar for both treatment groups
Selective reporting (reporting bias) Low risk All outcomes pre-specified in the registration record were reported
Other bias Unclear risk Investigator concerns resulting from the significantly increased mortality risk with the lower SpO 2 target range in the SUPPORT Trial publication led to an unscheduled safety analysis when 973 of the planned 1200 infants (81%) had been recruited. A decision was made to terminate recruitment in both the BOOST-II UK and BOOST-II Australia trials based on a pre-specified rule. There was an 8.5% excess in 36-week mortality in the low target group monitored with an oximeter incorporating the revised calibration software (data pooled from both studies, P < 0.001 with a significant treatment by software subgroup interaction, P = 0. 006). The early stopping of the trial (with 81% of the final planned sample size at that point) raises the question of whether this overestimates treatment effect 
